<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BE5027A2-9A29-4322-AB89-41E0AF3BC9FF"><gtr:id>BE5027A2-9A29-4322-AB89-41E0AF3BC9FF</gtr:id><gtr:name>MedImmune</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F5B83740-823A-461B-AEB6-0DCFED1739C8"><gtr:id>F5B83740-823A-461B-AEB6-0DCFED1739C8</gtr:id><gtr:name>Kyoto University</gtr:name><gtr:address><gtr:line1>Nishikyo-ku</gtr:line1><gtr:line2>Katsura Campus</gtr:line2><gtr:line4>Kyoto</gtr:line4><gtr:line5>Kyoto, 615-8540</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF"><gtr:id>37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF</gtr:id><gtr:name>MRC Toxicology Unit</gtr:name><gtr:address><gtr:line1>Hodgkin Building</gtr:line1><gtr:line2>University of Leicester</gtr:line2><gtr:line3>PO Box 138,  Lancaster Road</gtr:line3><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 9HN</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF"><gtr:id>37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF</gtr:id><gtr:name>MRC Toxicology Unit</gtr:name><gtr:address><gtr:line1>Hodgkin Building</gtr:line1><gtr:line2>University of Leicester</gtr:line2><gtr:line3>PO Box 138,  Lancaster Road</gtr:line3><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 9HN</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BE5027A2-9A29-4322-AB89-41E0AF3BC9FF"><gtr:id>BE5027A2-9A29-4322-AB89-41E0AF3BC9FF</gtr:id><gtr:name>MedImmune</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F5B83740-823A-461B-AEB6-0DCFED1739C8"><gtr:id>F5B83740-823A-461B-AEB6-0DCFED1739C8</gtr:id><gtr:name>Kyoto University</gtr:name><gtr:address><gtr:line1>Nishikyo-ku</gtr:line1><gtr:line2>Katsura Campus</gtr:line2><gtr:line4>Kyoto</gtr:line4><gtr:line5>Kyoto, 615-8540</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9F882B87-2C77-4ACE-9F10-D0CD957B3D36"><gtr:id>9F882B87-2C77-4ACE-9F10-D0CD957B3D36</gtr:id><gtr:firstName>Giovanna</gtr:firstName><gtr:surname>Mallucci</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U132692719"><gtr:id>E7DD8352-A48C-42EB-A4FA-BDE4B5FE6E3D</gtr:id><gtr:title>In vivo mechanisms of neurotoxicity</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U132692719</gtr:grantReference><gtr:abstractText>One of the greatest challenges in neuroscience, and to public health, is how to treat neurodegenerative diseases. These diseases involve the death of brain cells. When they are lost, the functions they control memory, movement and emotion are also irreversibly lost. In order to treat these disorders, we need to understand why brain cells degenerate and die. Most importantly, we need to understand the earliest stages of this process as this gives us the greatest chance of intervening to prevent cell death. I previously made a mouse model of prion disease in which early degeneration is reversible. In these mice, early structural changes in brain cells lead to changes in behaviour, memory and electrical signalling, very like early changes seen in human neurodegenerative disorders. Using either special genetic techniques we were able to reverse this process. The structural, behavioural and memory changes were all reversed and instead of dying, the mice recovered and lived a normal lifespan. We aim to understand the processes that control this recovery and use this to find targets for treating neurodegeneration.</gtr:abstractText><gtr:technicalSummary>Neurodegenerative diseases, such as Alzheimers, Parkinsons, Huntingtons disease and amyotrophic lateral sclerosis, have enormous clinical and economic impact world wide. Irrespective of the final pattern of clinical symptoms, they all are caused by an irreversible loss of neurons, which cannot be cured. But before neuronal death, there are neuronal dysfunction and synaptic impairment, which potentially can be treated.||My background is in prion diseases, modelling these in transgenic mice to look at mechanisms of neurotoxicity and developing new therapeutic approaches. In particular, I focused on the changes of early prion neurotoxicity and recovery from it. This new programme uses mouse models to understand the early molecular events in prion and other neurodegenerative diseases, looking in parallel at potential therapeutic targets for prevention of neuronal dysfunction and death.||Our main aims are to:|1. Characterise pre-degenerative neuronal changes.|2. Understand what triggers ultimate commitment to death in a malfunctioning neuron.|3. Define the molecular targets and the temporal window for functional recovery.||Initially, these questions will be addressed using our established mouse model of prion disease where early pathology is associated with a pivotal point in neuronal survival/death, and there is potential for recovery. We will use molecular biological, biochemical and neurophysiological techniques, as well as neuronal imaging in culture and in vivo to characterise the underlying cellular and synaptic changes, including alterations in signalling pathways and ion channels.||The broader aims of the programme are:|4. to generate new mouse models to look at individual pathways implicated in early dysfunction and their effect on neuronal function and death.|5. to address therapeutic strategies for the treatment of neurodegeneration.</gtr:technicalSummary><gtr:fund><gtr:end>2018-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>10674403</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cambridge Institute for Medical Research (CIMR)</gtr:department><gtr:description>pharmacokinetic studies on PERK inhibitors</gtr:description><gtr:id>CDDF2675-161A-4E44-9531-C8CD860DD810</gtr:id><gtr:impact>Oral treatment targeting the unfolded protein response prevents prion neurodegeneration and clinical disease in mice. Moreno JA, Halliday M, Molloy C, Axten JM, Willis AE, Ortori CA, Barrett DA, Fischer PM and Mallucci GR. Science Translational Medicine, 2013, 5,206ra138. 

Sustained translational repression by eIF2a-P mediates prion neurodegeneration. Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Guerra Martin M, Halliday M, Morgan J, Dinsdale D, Ortori CA, Barrett DA, Tsaytler P, Bertolotti A, Willis AE, M Bushell and Mallucci GR*. Nature 2012, 485, 507-11</gtr:impact><gtr:outcomeId>UXthfUnRkXZ-4</gtr:outcomeId><gtr:partnerContribution>PK and PD analyses
GSK supplied compounds
LC/MS-MS
Compound production</gtr:partnerContribution><gtr:piContribution>mechanism of neurodegeneration in prion disease and use of compounds to modulate disease progression</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Kyoto</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:department>Institute of Integrated Cell Material Sciences</gtr:department><gtr:description>Single molecule imaging of synaptic protein dynamics in neurodegeneration</gtr:description><gtr:id>FA9DA8E6-8F17-49FA-A020-51AECA594A5F</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>54624434e222c6.65611455-1</gtr:outcomeId><gtr:partnerContribution>Single-molecule imaging and super-resolution imaging o synaptic plasticity in primary neuronal cultures of wild type and neurodegenerative disease mouse models</gtr:partnerContribution><gtr:piContribution>Structural synaptic plasticity analysis in primary neuronal cultures of wild type and neurodegenerative disease mouse models</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>pharmacokinetic studies on PERK inhibitors</gtr:description><gtr:id>45621911-D9E7-45B8-A0F5-C7B2304FD889</gtr:id><gtr:impact>Oral treatment targeting the unfolded protein response prevents prion neurodegeneration and clinical disease in mice. Moreno JA, Halliday M, Molloy C, Axten JM, Willis AE, Ortori CA, Barrett DA, Fischer PM and Mallucci GR. Science Translational Medicine, 2013, 5,206ra138. 

Sustained translational repression by eIF2a-P mediates prion neurodegeneration. Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Guerra Martin M, Halliday M, Morgan J, Dinsdale D, Ortori CA, Barrett DA, Tsaytler P, Bertolotti A, Willis AE, M Bushell and Mallucci GR*. Nature 2012, 485, 507-11</gtr:impact><gtr:outcomeId>UXthfUnRkXZ-2</gtr:outcomeId><gtr:partnerContribution>PK and PD analyses
GSK supplied compounds
LC/MS-MS
Compound production</gtr:partnerContribution><gtr:piContribution>mechanism of neurodegeneration in prion disease and use of compounds to modulate disease progression</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Wolfson Brain Imaging Centre</gtr:department><gtr:description>In-vivo PET imagining of Neurodegeneration</gtr:description><gtr:id>29D37895-73EE-48AD-A42F-45652FE7803A</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>54623ca2de1645.07415275-1</gtr:outcomeId><gtr:partnerContribution>development and preparations of PET radiotracers for imaging research
PET data acquisition and analysis</gtr:partnerContribution><gtr:piContribution>mice for the study and biochemical and histological analyses for confirmation of disease progression and efficacy of treatment.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>ISRIB-like substances</gtr:description><gtr:id>628A2802-566C-48E3-9CCD-AA5248F69BD7</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>56d08483303b30.97964556-1</gtr:outcomeId><gtr:partnerContribution>generation of compounds
in vitro testing</gtr:partnerContribution><gtr:piContribution>we will test neuroprotective effects of new compounds in mice</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MedImmune</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>ISRIB-like substances</gtr:description><gtr:id>6F684F80-A2C2-406D-BB3C-3F769D29EF0D</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>56d08483303b30.97964556-2</gtr:outcomeId><gtr:partnerContribution>generation of compounds
in vitro testing</gtr:partnerContribution><gtr:piContribution>we will test neuroprotective effects of new compounds in mice</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>GSK Oncology</gtr:department><gtr:description>pharmacokinetic studies on PERK inhibitors</gtr:description><gtr:id>97693DAC-AC5E-476B-BA28-0BF2E1A0AA80</gtr:id><gtr:impact>Oral treatment targeting the unfolded protein response prevents prion neurodegeneration and clinical disease in mice. Moreno JA, Halliday M, Molloy C, Axten JM, Willis AE, Ortori CA, Barrett DA, Fischer PM and Mallucci GR. Science Translational Medicine, 2013, 5,206ra138. 

Sustained translational repression by eIF2a-P mediates prion neurodegeneration. Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Guerra Martin M, Halliday M, Morgan J, Dinsdale D, Ortori CA, Barrett DA, Tsaytler P, Bertolotti A, Willis AE, M Bushell and Mallucci GR*. Nature 2012, 485, 507-11</gtr:impact><gtr:outcomeId>UXthfUnRkXZ-3</gtr:outcomeId><gtr:partnerContribution>PK and PD analyses
GSK supplied compounds
LC/MS-MS
Compound production</gtr:partnerContribution><gtr:piContribution>mechanism of neurodegeneration in prion disease and use of compounds to modulate disease progression</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Medicinal and Biological Chemistry</gtr:department><gtr:description>pharmacokinetic studies on PERK inhibitors</gtr:description><gtr:id>7BCEA89E-211E-42D2-8ABE-3286AE52D33D</gtr:id><gtr:impact>Oral treatment targeting the unfolded protein response prevents prion neurodegeneration and clinical disease in mice. Moreno JA, Halliday M, Molloy C, Axten JM, Willis AE, Ortori CA, Barrett DA, Fischer PM and Mallucci GR. Science Translational Medicine, 2013, 5,206ra138. 

Sustained translational repression by eIF2a-P mediates prion neurodegeneration. Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Guerra Martin M, Halliday M, Morgan J, Dinsdale D, Ortori CA, Barrett DA, Tsaytler P, Bertolotti A, Willis AE, M Bushell and Mallucci GR*. Nature 2012, 485, 507-11</gtr:impact><gtr:outcomeId>UXthfUnRkXZ-1</gtr:outcomeId><gtr:partnerContribution>PK and PD analyses
GSK supplied compounds
LC/MS-MS
Compound production</gtr:partnerContribution><gtr:piContribution>mechanism of neurodegeneration in prion disease and use of compounds to modulate disease progression</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>radio interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>26A9A232-662A-4C10-B589-F60724F0543E</gtr:id><gtr:impact>http://www.thenakedscientists.com/HTML/podcasts/naked-scientists/show/20160119/</gtr:impact><gtr:outcomeId>58b98ee8270339.94105738</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.thenakedscientists.com/HTML/podcasts/naked-scientists/show/20160119/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>work highlighted British Neuroscience Bulletin 2012</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>924DA6F0-C6AB-49A4-9B12-CB090084337A</gtr:id><gtr:impact>highlight of groups reseracj

generated much interest adn phd applications</gtr:impact><gtr:outcomeId>agXmaFLQsCx</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>nottingham inspire</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6F71EFBB-D049-42E3-9353-101BEC7C1D2B</gtr:id><gtr:impact>400 medical students 
careers in science and medicine</gtr:impact><gtr:outcomeId>56d08be2d5e2f8.73697397</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>press interviews 2008</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D86D4B18-46ED-42B2-A73D-A07A6B068124</gtr:id><gtr:impact>press interviews broadsheets science journals BBC Radio 4 science now

widespread dissemination of research</gtr:impact><gtr:outcomeId>F0E8EA61886</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>media interviews 2007</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>27D2CBC7-8FE0-403D-B682-AA68AB2317D2</gtr:id><gtr:impact>numerous interviews to BBC radio, US radio 
science press
national press

widespread reporting in science and mass media
radio 4 interview 'science now'</gtr:impact><gtr:outcomeId>L7ppeDGPtqZ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC radio interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>893201BF-9D29-4B86-95C3-4B7C0B4F57EF</gtr:id><gtr:impact>naked scientist radio interview about hibernation and Alzheimer's</gtr:impact><gtr:outcomeId>56d08ba44edf59.95209154</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.thenakedscientists.com/HTML/podcasts/naked-scientists/show/20160119/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media interviews for STM paper 2013</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C56883CD-857D-4F4B-9D5F-568799CE42ED</gtr:id><gtr:impact>MRC scientists halt neurodegeneration in mice (BBC 4 Today programme, 07.12) also interviews on BBC, ITV, Channel 5, Sky, CNN, ABC, Al jazeera, local radio-stations
The Independent (front page) with additional online commentary
The Daily Express (front page)
Daily Mirror (front page)
The Sun (page 4) Online version unavailable
Daily Mail (page 5)
The Guardian (page 6)
The Daily Record (page 5)
The Scotsman p13
The Herald p5 Online version unavailable
BBC online
ITV
Sky News 
Channel 4
The Daily Telegraph (page 14)
 
The story was also reported without an MRC mention in The Times (front page, online version unavailable) 
 
Plus...innumerable regional newspapers, radio and TV outlets - particularly in the Leicester area!! - and international outlets from CNN to ABC to The Times of India, Time magazine, Spanish, Italian, Brazilian, Polish, Turkish, French and German outlets. 
A pill for neurodegenerative disease? Not yet, but we're getting closer (BBC News Online)
The Guardian
SKY News
BBC World Service 
ITV
BBC World Business Report
Radio 5
BBC Breakfast
 
The Daily Mirror (page 8) highlighted the research and asked what other diseases can we hope to defeat. Online version unavailable
The Sunday Times, News Review page 2, Vivienne Parry
 (BBC News Online) The Guardian
SKY News
BBC World Service
ITV
BBC World Business Report
Radio 5
 
The Daily Mirror (page 8) highlighted the research and asked what other diseases can we hope to defeat. Online version unavailable
The Sunday Times, News Review page 2, Vivienne Parry

Huge interest into the Unit's research</gtr:impact><gtr:outcomeId>arCS6vfMSJn</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Unit Open Day 2013</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FF09A330-FDBF-4541-966B-4C78B1F276FD</gtr:id><gtr:impact>Over 500 members of the public visited the Unit

Members of the public were very appreciative.
Students asked to come and carry out work experience in the Unit.</gtr:impact><gtr:outcomeId>E5hrZVUaXQn</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://tox.mrc.ac.uk/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Anne Silk Lecturer, Royal Society of Medicine, London, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>01300F78-6AD0-4ACD-A9DC-9B79437426D7</gtr:id><gtr:impact>public lecture on progress in treatment of neurodegeneration</gtr:impact><gtr:outcomeId>56d08965326da7.46690813</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.rsm.ac.uk/events/events-listing/2013-2014/groups/public-engagement-programme/pee07-anne-silk-lecture-neurodegeneration-from-molecules-to-medicines.aspx</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>biology in action</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4500180C-8150-4453-974C-21D92A95CACB</gtr:id><gtr:impact>Biology in Action is a very popular annual day, which sets out to give students a stimulating day of biology in five wide-ranging sessions, and helps them and their teachers keep up to date with developments and issues. We aim to provide students with inspiration to pursue their studies at a higher level through talks that go beyond the curriculum.</gtr:impact><gtr:outcomeId>56d08a0fa374c5.54745992</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Frank May Medal for Excellence in Research and Outstanding Future Promise; University of Leicester, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4323B17E-B98D-494E-BAC0-6D904483B681</gtr:id><gtr:impact>public lecture discussing medical advances</gtr:impact><gtr:outcomeId>56d089ca780131.48883963</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>toxicology open day 2010</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>786592C9-5D70-48F3-A257-0973C489CBBC</gtr:id><gtr:impact>presentation to graduate students

top performer voted by students!</gtr:impact><gtr:outcomeId>N5WePEfV1G1</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Festival in Genova 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AE9E9A31-509C-4A11-BEA1-2FBEC870C02C</gtr:id><gtr:impact>public interest high

public interest</gtr:impact><gtr:outcomeId>Jp2hbHTa7fr</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>work experience</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A03231F6-0DA7-42C1-9E80-A21F167C11FA</gtr:id><gtr:impact>work student for 1 week in my lab
work experience undergraduate for 10wks

positive experience further applicants</gtr:impact><gtr:outcomeId>NYM6TauQLm5</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>28th Cambridge Festival of Neuroscience Keynote lecture &quot;The treatment of dementia: new directions&quot;, Cambridge, UK, March 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>468A65D3-8D44-41FE-811F-295B29139611</gtr:id><gtr:impact>Public lecture: 28th Cambridge Festival of Neuroscience: &amp;quot;The treatment of dementia: new directions&amp;quot;, Cambridge, UK, March 2016</gtr:impact><gtr:outcomeId>58b98e70c90654.62694738</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC PEN event</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9A5423EB-2215-40FB-BEE5-D61A9BD15121</gtr:id><gtr:impact>public panel debate between writers and scientists &amp;quot; barriers to creativity&amp;quot; 
Royal geographical society
public debate and questions

MRC website
PEN website</gtr:impact><gtr:outcomeId>aeYQSBs6vU3</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>East midlands medical student conference: Keynote 'INSPIRE' lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>58852FB8-01C1-4330-B5C3-354BFD3F7145</gtr:id><gtr:impact>unknown</gtr:impact><gtr:outcomeId>5463515c8aaa84.94940649</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>schools careers in science talks</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7F960958-326C-4B18-9A50-A79EE22AD95F</gtr:id><gtr:impact>pupils interested in science
work experience in my lab

work experience and science interests</gtr:impact><gtr:outcomeId>gBjVEV6ve4W</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK Conference of Science Journalists 2012</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>958E2A49-5BD7-4432-A161-A3C28D0A90D9</gtr:id><gtr:impact>dialogue with science writers

interest in science reporting</gtr:impact><gtr:outcomeId>mRbezoHn64s</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>mrc annual report</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>88F74144-95FD-42E9-9109-BBA9874F2D5B</gtr:id><gtr:impact>interviewed as one of MRC's 'people behind discovery'

positive feedback, applicants to work with me</gtr:impact><gtr:outcomeId>nLGmG6TJwKC</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Television interviews</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>252A9BF0-9123-4C41-882D-4D6CEEE7F7A9</gtr:id><gtr:impact>discussed our research which was hailed as &amp;quot;turning point in search for medicines to control and prevent Alzheimer's&amp;quot;</gtr:impact><gtr:outcomeId>56d08a9c698aa2.59536129</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/health-24462699.</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Plenary speaker and panelist at International Monetary Fund First TalentNomics Conference: Innovation, Economic Growth, and the Empowerment of Women, Washington DC, USA, November 2015.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>36675B9B-2A33-4467-B40F-68EFC3C504B5</gtr:id><gtr:impact>Plenary speaker and panelist at International Monetary Fund First TalentNomics Conference: Innovation, Economic Growth, and the Empowerment of Women, Washington DC, USA, November 2015.</gtr:impact><gtr:outcomeId>58b98f3331aa91.23721794</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>nottingham inspire</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>638C2B51-32DC-4BB5-9DE6-95D26F4FF0C2</gtr:id><gtr:impact>400 medical students 
careers in science and medicine</gtr:impact><gtr:outcomeId>56d08bdf9fd5d0.79366680</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nature podcast</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>29D47291-FB45-4BC8-A653-F2F0608DC807</gtr:id><gtr:impact>nature podcast about discovery of hibernation and synaptic regeneration and role in neuroprotection</gtr:impact><gtr:outcomeId>56d08b49d3e269.66768206</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.nature.com/nature/podcast/index-2015-01-15.html</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1800000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>consolidator award</gtr:description><gtr:end>2021-03-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:id>0F1E82E4-B270-4DED-8CBB-B5D82B4450B2</gtr:id><gtr:outcomeId>58b98b97389455.51960505</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>ERC consolidator award</gtr:description><gtr:end>2020-08-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:fundingRef>UPR-?Neuro 647479</gtr:fundingRef><gtr:id>7B1909B9-4477-4F27-86B8-2851382B7847</gtr:id><gtr:outcomeId>56d085537c9d14.31573478</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>RG79399</gtr:fundingRef><gtr:id>8FA3FA0E-4ADC-408E-8250-F90230E8378A</gtr:id><gtr:outcomeId>56d085908b9776.97365167</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>experimental medicine grant</gtr:description><gtr:end>2019-06-02</gtr:end><gtr:fundingOrg>MRC Dementias Platform UK</gtr:fundingOrg><gtr:id>8CCA55DB-9B60-4C65-AB2D-10E12F58FB1F</gtr:id><gtr:outcomeId>58b98b3481bf79.51656650</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NEUROPRION Use of RNAi for treatment of inherited prion disease (14.4m euros across 41 participants)</gtr:description><gtr:end>2009-08-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>8EBEE40B-1677-4ED6-B10D-79147665A451</gtr:id><gtr:outcomeId>F83FD15D3080</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Toxicology Unit</gtr:department><gtr:description>MRC intramural programme funding</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>EA910A21-C2FE-44E3-93A7-E77323A3F6F3</gtr:id><gtr:outcomeId>56d08626a87849.80164519</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Alz Soc/ADDF Drug repuprosing</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Alzheimer?s Society</gtr:fundingOrg><gtr:id>C2DC8C82-FD24-40D6-8308-57FC830B68D9</gtr:id><gtr:outcomeId>56d085d7f15e24.26100140</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of MRC Neuroscience and Mental Health Board</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BABD6034-880F-4763-B591-46FD98811D50</gtr:id><gtr:outcomeId>58b98ff6670522.11519917</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRC Neuroscience strategy board</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F00E031C-F0C1-4770-9421-B1C14C153612</gtr:id><gtr:outcomeId>tqjS6VZG34f</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Chair, UK-India Joint Centre Partnerships Panel (MRC-DPT)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>076BB5E3-8E79-4953-B604-6EEDF6BB1FAD</gtr:id><gtr:outcomeId>54635de0353b21.48241214</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>RSM clinical neuroscience council</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>D56D7F8E-F109-404A-A0FC-3FDA5F54EBB5</gtr:id><gtr:outcomeId>fiuVEwEjjmY</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>leicester neuroscience steering committee</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>96087332-2DF7-4F8C-844A-C222E35A9C66</gtr:id><gtr:outcomeId>Dj6YrMSFGd2</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>cre deleter mice in neurons
floxed prp mice
crossed led to adult onset knockout of prp in neurons</gtr:description><gtr:id>445E12AC-9705-45EF-BBAB-2D6659ED64EA</gtr:id><gtr:impact>reversal prion disease widely used mouse model</gtr:impact><gtr:outcomeId>rrb1ZQFHKHB</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>NFH-Cre/MloxP mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>53C5B949-B51F-42F1-B39D-2A9CE03AFE60</gtr:id><gtr:title>miRNAs-19b, -29b-2* and -339-5p show an early and sustained up-regulation in ischemic models of stroke.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6d8c307abe47ce905f84c424ac37145"><gtr:id>a6d8c307abe47ce905f84c424ac37145</gtr:id><gtr:otherNames>Dhiraj DK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>As9Gf95u9rw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0B12725-35DD-4E73-AACC-AD547AE58506</gtr:id><gtr:title>Mitofusin-mediated ER stress triggers neurodegeneration in pink1/parkin models of Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cd5d10f841c27e2f13c2b8f63b6c177"><gtr:id>2cd5d10f841c27e2f13c2b8f63b6c177</gtr:id><gtr:otherNames>Celardo I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58b98d08966ae3.43800207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48793E13-9B05-4D63-92FE-5E96F521404A</gtr:id><gtr:title>Fine-tuning PERK signaling for neuroprotection.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4c6af0c38a78606ae062de8c732b1e0"><gtr:id>d4c6af0c38a78606ae062de8c732b1e0</gtr:id><gtr:otherNames>Halliday M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>5a9ec78cb436c0.21084467</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E17AD83F-96C1-43CF-92CC-919FEF660D38</gtr:id><gtr:title>Targeted knock-down of cellular prion protein expression in myelinating Schwann cells does not alter mouse prion pathogenesis.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4583d2e0c3628afec83975bf615f1319"><gtr:id>4583d2e0c3628afec83975bf615f1319</gtr:id><gtr:otherNames>Halliez S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>pm_14120_20_23388201</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42ED500C-E10B-49AC-875E-6B2B48E246DB</gtr:id><gtr:title>Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c24855ecb6f14958c378c4a4b3352d2f"><gtr:id>c24855ecb6f14958c378c4a4b3352d2f</gtr:id><gtr:otherNames>Tufi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn><gtr:outcomeId>KSyW2xJm23F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6B7AF1C-4910-453F-A534-05B5C6D666B0</gtr:id><gtr:title>Therapy for prion diseases: Insights from the use of RNA interference.</gtr:title><gtr:parentPublicationTitle>Prion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1601e9c67e7ea4bd5dad6d3ae17192c"><gtr:id>c1601e9c67e7ea4bd5dad6d3ae17192c</gtr:id><gtr:otherNames>White MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1933-6896</gtr:issn><gtr:outcomeId>sbz7g4fiK7k</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65E59DC2-5A2F-4F8E-B578-059ADF3C8F40</gtr:id><gtr:title>Update on Creutzfeldt-Jakob disease.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90cffc3bbd002d1184acf786baea9f47"><gtr:id>90cffc3bbd002d1184acf786baea9f47</gtr:id><gtr:otherNames>Mallucci G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>1350-7540</gtr:issn><gtr:outcomeId>pm_14120_10_15542971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>531A62F0-7463-4C51-B941-3E9755F48A59</gtr:id><gtr:title>RNAi for the treatment of prion disease: a window for intervention in neurodegeneration?</gtr:title><gtr:parentPublicationTitle>CNS &amp; neurological disorders drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1601e9c67e7ea4bd5dad6d3ae17192c"><gtr:id>c1601e9c67e7ea4bd5dad6d3ae17192c</gtr:id><gtr:otherNames>White MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1871-5273</gtr:issn><gtr:outcomeId>nhf4ZHLKSnP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81EE252C-4A67-4C95-90D1-6CCDE3876857</gtr:id><gtr:title>Dysfunction and recovery of synapses in prion disease: implications for neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a45accd461e1e9d4d6142f0ea8b377b"><gtr:id>4a45accd461e1e9d4d6142f0ea8b377b</gtr:id><gtr:otherNames>Moreno JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>ENBCEt21cXQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F990BA3-73F7-41E3-9326-D5DC47F857E3</gtr:id><gtr:title>Prions: generation and spread versus neurotoxicity.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4c6af0c38a78606ae062de8c732b1e0"><gtr:id>d4c6af0c38a78606ae062de8c732b1e0</gtr:id><gtr:otherNames>Halliday M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>5461f5ff22dda9.84134010</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19C71412-EE4A-465E-95A8-B1EB5D61E75B</gtr:id><gtr:title>Rational targeting for prion therapeutics.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90cffc3bbd002d1184acf786baea9f47"><gtr:id>90cffc3bbd002d1184acf786baea9f47</gtr:id><gtr:otherNames>Mallucci G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1471-003X</gtr:issn><gtr:outcomeId>pm_14120_10_15611724</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>223C73E9-35DF-4314-991B-4DE1210F26C3</gtr:id><gtr:title>Rescuing neurons in prion disease.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/176e57771a74564a08aa5ee42a02c1ed"><gtr:id>176e57771a74564a08aa5ee42a02c1ed</gtr:id><gtr:otherNames>Verity NC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>pm_14120_20_21158739</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01668FD7-1301-4112-8597-944BDC5DE8B8</gtr:id><gtr:title>RTN3 Is a Novel Cold-Induced Protein and Mediates Neuroprotective Effects of RBM3.</gtr:title><gtr:parentPublicationTitle>Current biology : CB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/638c314c0ef6e190e8a7f3529ecb699f"><gtr:id>638c314c0ef6e190e8a7f3529ecb699f</gtr:id><gtr:otherNames>Bastide A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0960-9822</gtr:issn><gtr:outcomeId>58b98ce0cfc7c0.51419460</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BEA888BC-533F-42D1-9C47-A4F85AE227C7</gtr:id><gtr:title>The unfolded protein response in neurodegenerative disorders - therapeutic modulation of the PERK pathway.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03db2458b85a51d20f3a242bb7b7fd4b"><gtr:id>03db2458b85a51d20f3a242bb7b7fd4b</gtr:id><gtr:otherNames>Hughes D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>5a9ec78c8509d0.74694610</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4F7820D-C164-424C-867E-CF8F2CB39E59</gtr:id><gtr:title>Repurposed drugs targeting eIF2a-P-mediated translational repression prevent neurodegeneration in mice.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4c6af0c38a78606ae062de8c732b1e0"><gtr:id>d4c6af0c38a78606ae062de8c732b1e0</gtr:id><gtr:otherNames>Halliday M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5a9ec78d10af70.89591613</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69772CEA-AA3D-42E5-9D40-38EB0257873A</gtr:id><gtr:title>PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b63bf0ee58edc8bb7309751c416fdc30"><gtr:id>b63bf0ee58edc8bb7309751c416fdc30</gtr:id><gtr:otherNames>Radford H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>56d08341e62724.55689293</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAA94786-142E-4DE4-8B99-92C773D5875E</gtr:id><gtr:title>Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35f86b9d72c7d61cef5193d5228058e6"><gtr:id>35f86b9d72c7d61cef5193d5228058e6</gtr:id><gtr:otherNames>Mallucci GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>ckrXg8S9AD9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E43D980-8FEB-45E5-8305-B43265CBF8F4</gtr:id><gtr:title>Cooling-induced SUMOylation of EXOSC10 down-regulates ribosome biogenesis.</gtr:title><gtr:parentPublicationTitle>RNA (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bb43eadc376abbf6c6d96b46a2f16b0"><gtr:id>2bb43eadc376abbf6c6d96b46a2f16b0</gtr:id><gtr:otherNames>Knight JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1355-8382</gtr:issn><gtr:outcomeId>56d08378eb4de5.27220114</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D42E3D1-E1FF-4C8F-A65F-ED9D46E01926</gtr:id><gtr:title>Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4c6af0c38a78606ae062de8c732b1e0"><gtr:id>d4c6af0c38a78606ae062de8c732b1e0</gtr:id><gtr:otherNames>Halliday M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d0834235b706.13023737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CC4F06D-20DC-44C3-A8CE-3EFC3F49F742</gtr:id><gtr:title>Can mutations of prion protein shed light on its normal function?</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35f86b9d72c7d61cef5193d5228058e6"><gtr:id>35f86b9d72c7d61cef5193d5228058e6</gtr:id><gtr:otherNames>Mallucci GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>oVWwTWQNRuz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CD62D1F-FBAA-48FE-A789-92D0E6352E63</gtr:id><gtr:title>Inherited prion disease with an alanine to valine mutation at codon 117 in the prion protein gene.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35f86b9d72c7d61cef5193d5228058e6"><gtr:id>35f86b9d72c7d61cef5193d5228058e6</gtr:id><gtr:otherNames>Mallucci GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1999-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_14120_10_10506086</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3267FD9D-8537-41FB-ABD1-766CA3E48C46</gtr:id><gtr:title>Spreading proteins in neurodegeneration: where do they take us?</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90cffc3bbd002d1184acf786baea9f47"><gtr:id>90cffc3bbd002d1184acf786baea9f47</gtr:id><gtr:otherNames>Mallucci G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_14120_20_23518708</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7ECEDEE3-07E3-4F9A-BBD0-1B43E4F53C57</gtr:id><gtr:title>Review: Modulating the unfolded protein response to prevent neurodegeneration and enhance memory.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4c6af0c38a78606ae062de8c732b1e0"><gtr:id>d4c6af0c38a78606ae062de8c732b1e0</gtr:id><gtr:otherNames>Halliday M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>56d08342653605.31836527</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>786F6D02-2DDB-440A-83C9-189A2B8B8144</gtr:id><gtr:title>Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1601e9c67e7ea4bd5dad6d3ae17192c"><gtr:id>c1601e9c67e7ea4bd5dad6d3ae17192c</gtr:id><gtr:otherNames>White MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>C5E8C3C067B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50A28FCB-3387-4077-9482-F8E1FA2E4E5D</gtr:id><gtr:title>The unfolded protein response: mechanisms and therapy of neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f53b11de0d73641d654e1123e43facda"><gtr:id>f53b11de0d73641d654e1123e43facda</gtr:id><gtr:otherNames>Smith HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>58b98d2252bef8.53009065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B4F5661-A3BF-4E4E-BDCB-1D747C47394A</gtr:id><gtr:title>M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/655e2cbad5f6560f048d3541e90b0d96"><gtr:id>655e2cbad5f6560f048d3541e90b0d96</gtr:id><gtr:otherNames>Bradley SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>58b98cba309dd7.26196132</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4223E00D-04B7-485F-9043-487E5D4BE26E</gtr:id><gtr:title>Update on the Pathophysiology of Prion Diseases</gtr:title><gtr:parentPublicationTitle>ACNR</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa87a1cd286d20136b882e27ad2ac046"><gtr:id>fa87a1cd286d20136b882e27ad2ac046</gtr:id><gtr:otherNames>Verity N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5462243feaec67.81660319</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23583415-5AFA-41EF-8770-EF359DF9D935</gtr:id><gtr:title>RBM3 mediates structural plasticity and protective effects of cooling in neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0042775cd42f8bf4ca5f19c31c440848"><gtr:id>0042775cd42f8bf4ca5f19c31c440848</gtr:id><gtr:otherNames>Peretti D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>5675decfdfa3a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFBB50D7-36FA-4619-AABF-6067D43BAF95</gtr:id><gtr:title>Targeting the unfolded protein response in neurodegeneration: A new approach to therapy.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4c6af0c38a78606ae062de8c732b1e0"><gtr:id>d4c6af0c38a78606ae062de8c732b1e0</gtr:id><gtr:otherNames>Halliday M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>pm_14120_20_24035917</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8EB2DEE-80AD-421D-837B-0D5A0D4AF0D9</gtr:id><gtr:title>Reply: Trazodone to change the risk of neurodegeneration: bedside to bench.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4c6af0c38a78606ae062de8c732b1e0"><gtr:id>d4c6af0c38a78606ae062de8c732b1e0</gtr:id><gtr:otherNames>Halliday M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5a9ec78cdfe8f7.32322654</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE4C235F-0178-4CBC-BF28-5143242DA4E5</gtr:id><gtr:title>Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35f86b9d72c7d61cef5193d5228058e6"><gtr:id>35f86b9d72c7d61cef5193d5228058e6</gtr:id><gtr:otherNames>Mallucci GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2002-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>pm_14120_10_11823413</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00726FD3-71A9-4E2E-88BC-D90DC4E3D6CF</gtr:id><gtr:title>Prion neurodegeneration: starts and stops at the synapse.</gtr:title><gtr:parentPublicationTitle>Prion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35f86b9d72c7d61cef5193d5228058e6"><gtr:id>35f86b9d72c7d61cef5193d5228058e6</gtr:id><gtr:otherNames>Mallucci GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1933-6896</gtr:issn><gtr:outcomeId>GJAvxVTStHN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D8AA51D-B9B0-41A0-826A-589CBA65A92B</gtr:id><gtr:title>Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a45accd461e1e9d4d6142f0ea8b377b"><gtr:id>4a45accd461e1e9d4d6142f0ea8b377b</gtr:id><gtr:otherNames>Moreno JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>pm_14120_20_24107777</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D9B9CB2-4837-4808-AD7D-3CC9449BBDD8</gtr:id><gtr:title>Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90cffc3bbd002d1184acf786baea9f47"><gtr:id>90cffc3bbd002d1184acf786baea9f47</gtr:id><gtr:otherNames>Mallucci G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>pm_14120_10_14593181</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CF4C270-4A8C-4DE4-A258-623C57F233FA</gtr:id><gtr:title>The UPR and synaptic dysfunction in neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Brain research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cd113ac8c911ef69da79991bbe3298b"><gtr:id>4cd113ac8c911ef69da79991bbe3298b</gtr:id><gtr:otherNames>Freeman OJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-8993</gtr:issn><gtr:outcomeId>58b98d41bd0562.06525230</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4ED9FD81-4790-4298-BA21-40B0B4FE9CB1</gtr:id><gtr:title>Targeting synaptic pathology with a novel affinity mass spectrometry approach.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular proteomics : MCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be3dcca24b1cd57b2185c45891e94495"><gtr:id>be3dcca24b1cd57b2185c45891e94495</gtr:id><gtr:otherNames>Brinkmalm A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1535-9476</gtr:issn><gtr:outcomeId>5461f5ff4b5749.24983999</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC2D50FF-0114-4555-93EF-535B6BE73DB6</gtr:id><gtr:title>Sustained translational repression by eIF2a-P mediates prion neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a45accd461e1e9d4d6142f0ea8b377b"><gtr:id>4a45accd461e1e9d4d6142f0ea8b377b</gtr:id><gtr:otherNames>Moreno JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>pm_14120_20_22622579</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>186D2E36-BDED-4F4D-AB05-23160E613F5D</gtr:id><gtr:title>Nerve injury induces robust allodynia and ectopic discharges in Nav1.3 null mutant mice.</gtr:title><gtr:parentPublicationTitle>Molecular pain</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cc0219873a39ba68d81717aa20a8ab9"><gtr:id>9cc0219873a39ba68d81717aa20a8ab9</gtr:id><gtr:otherNames>Nassar MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1744-8069</gtr:issn><gtr:outcomeId>455C2EAF206</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F06DC878-ABDB-4029-845C-7D745E4C36A7</gtr:id><gtr:title>The role of GPI-anchored PrP C in mediating the neurotoxic effect of scrapie prions in neurons.</gtr:title><gtr:parentPublicationTitle>Current issues in molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56d99597304c2ceddf5e693f3dc27c46"><gtr:id>56d99597304c2ceddf5e693f3dc27c46</gtr:id><gtr:otherNames>Radford HE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1467-3037</gtr:issn><gtr:outcomeId>dVi4X9kwEjM</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U132692719</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>